To view the PDF file, sign up for a MySharenet subscription.

ASCENDIS HEALTH LIMITED - Media coverage relating to drugs in the treatment of patients with COVID-19

Release Date: 18/06/2020 17:25
Code(s): ASC     PDF:  
Wrap Text
Media coverage relating to drugs in the treatment of patients with COVID-19

Ascendis Health Limited
(Registration number 2008/005856/06)
(Incorporated in the Republic of South Africa)
Share code: ASC
ISIN: ZAE000185005
(“Ascendis Health” or “the Company”)




Media coverage relating to drugs in the treatment of patients with COVID-19

Ascendis Health has noted the media coverage relating to the preliminary results of a drug trial using
dexamethasone in the treatment of patients with COVID-19 requiring respiratory intervention.

In line with the General Principles of the JSE Listings Requirements to ensure that full, equal and
timeous public disclosure is made to all shareholders of Ascendis Health and the general public at
large regarding the activities of the Company that may be price sensitive, Ascendis Health hereby
confirms that Remedica, a wholly owned subsidiary of Ascendis Health based in Cyprus, produces
tablets containing dexamethasone, under the name Perazone, however such drug is limited to the
Tanzanian market only.


Bryanston
18 June 2020

Sponsor
Questco Corporate Advisory Proprietary Limited

Date: 18-06-2020 05:25:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.

Share This Story